METTL3: Melting the tumor microenvironment for improved immunotherapy

Longfei Gao; Lei Ding

doi:10.1016/j.chembiol.2024.03.005

METTL3: Melting the tumor microenvironment for improved immunotherapy

Cell Chem Biol. 2024 Apr 18;31(4):629-631. doi: 10.1016/j.chembiol.2024.03.005.

Authors

Longfei Gao¹, Lei Ding²

Affiliations

¹ Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA.
² Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: [email protected].

PMID: 38640901
DOI: 10.1016/j.chembiol.2024.03.005

Abstract

The tumor microenvironment (TME) dictates the outcome of cancer immunotherapy. In this issue of Cell Chemical Biology, Yu et al.¹ report that targeting Mettl3 leads to a more inflamed, "hot" TME and effective anti-PD-1 therapy. This study points to a new target in remodeling the TME for improved immunotherapy.

MeSH terms

Immunotherapy*
Tumor Microenvironment*